KPV

KPV is a tripeptide composed of the amino acids lysine, proline, and valine (Lys-Pro-Val), corresponding to residues 11 to 13 at the C-terminus of alpha-melanocyte-stimulating hormone (alpha-MSH). alpha-MSH is a thirteen-amino-acid hormone produced from proopiomelanocortin that has long been recognized for potent anti-inflammatory activity, and a substantial body of work has traced much of that activity to this short terminal fragment ^[1][3][4].

The scientific interest in KPV rests on a useful separation of functions. Whereas the full alpha-MSH hormone also drives pigmentation through melanocortin receptors, KPV retains most of the anti-inflammatory capacity while lacking the pigmentary effect, which makes it attractive as a therapeutic lead ^[4]. Research has examined KPV in models of inflammatory bowel disease, contact dermatitis, peritonitis, ocular and airway inflammation, and arthritis, where it consistently dampens inflammatory responses ^[1][3][4]. A frequently cited study demonstrated that orally administered KPV reduced the severity of experimental colitis in mice ^[2].

KPV is a synthetic peptide when produced for research and is supplied as a lyophilized powder for reconstitution; a related dimer, (CKPV)2, has separately been explored for antimicrobial and anti-inflammatory uses. KPV is not an approved drug and is sold for research purposes. Its combination of small size, low expected production cost, favorable physicochemical properties, and a mechanism that targets inflammation rather than broadly suppressing immunity is the central reason it remains a peptide of ongoing interest for gut and skin conditions.

There is no controlled human safety data for KPV. No clinical trial of the tripeptide is registered or published, and the closest the literature comes to human exposure is ex vivo human skin and cultured human cell lines. What follows is what has actually been measured, and the route it was measured by, because KPV behaves very differently depending on how it is given.

The most useful safety-relevant result is a negative one about skin. Applied to intact human skin, KPV did not cross at a detectable level by passive diffusion; it moved only after the skin was microporated with microneedles or driven by an iontophoretic current, and every one of those treatments also raised the amount of peptide retained inside the skin rather than delivered through it ^[15]. A topical preparation is therefore not a systemic route by default, and a cream that produces no effect is behaving exactly as that experiment predicts.

In the gut, the route the compound is best characterised for, KPV enters intestinal epithelial and immune cells through the PepT1 transporter, which is induced in inflamed colon ^[2]. Colon-targeted nanoparticles used to deliver it did not affect cell viability or barrier function in cultured intestinal epithelium, and reduced colitis in mice while carrying the peptide at a concentration roughly four orders of magnitude below what free peptide in solution required for the same effect ^[26]. On other mucosal surfaces the picture is similar. Topical drops in rabbits accelerated corneal re-epithelialisation, with all treated corneas closed by the end of the observation period ^[17], and a mucoadhesive KPV hydrogel applied to the gingival mucosa of rats with chemotherapy-induced oral mucositis improved food intake and body weight recovery ^[18]. In mice, KPV co-assembled with rapamycin into carrier-free nanoparticles was reported to show good stability and biosafety alongside its effect on vascular calcification ^[25].

Cell-level tolerability has been reported directly rather than inferred. KPV restored viability in human keratinocytes damaged by fine particulate matter and reduced their IL-1beta output ^[21], and in HepG2 hepatocytes it reduced lipid accumulation without inducing cytotoxicity at the concentration used ^[20]. In human bronchial epithelial cells it suppressed NF-kB signalling by blocking nuclear import of p65RelA ^[19], which is a targeted interference with one transcription factor rather than a general shutdown of immunity.

The question that follows from any anti-inflammatory is whether it blunts host defence, and here there is affirmative evidence pointing the other way. alpha-MSH peptides including the C-terminal tripeptide inhibited Staphylococcus aureus colony formation and reduced Candida albicans viability directly, and rather than reducing killing of those pathogens by human neutrophils they increased it ^[27]. That is a measured result, not an absence of complaints.

Two pieces of evidence say clearly that the parent hormone's long pharmacological record cannot be borrowed as reassurance. KPV does not contain the sequence motif needed to bind any known melanocortin receptor, and its intracellular target is still unidentified ^[23]. And where alpha-MSH potently suppressed basophil activation through MC-1R in blood from healthy and allergic donors, KPV did not reproduce that effect at all ^[22]. A fragment that does not do what the hormone does cannot inherit the hormone's safety profile in either direction.

Handling matters more than the compound's simplicity suggests. Under acid, alkali and hydrogen peroxide stress, KPV degrades chiefly to lys-pro-diketopiperazine ^[16]. That degradant has no toxicology of its own, so an old, warm or discoloured solution is not simply a weaker one; it is a solution containing something that has not been characterised.

The last risk is the supply itself. A 2026 critical review of peptide use in sport and bodybuilding names KPV among the synthetic fragments now circulating, notes that published work covers therapeutic dosing rather than the supraphysiological or stacked protocols used in practice, and describes a largely unregulated supply chain in which products are often mislabelled or contaminated; its conclusion is that such use should be treated as high risk until longitudinal data exist ^[24]. A specific instance of that mislabelling applies here: a large share of material sold as KPV is the N-acetylated and C-amidated analogue rather than the free peptide, so the name on the vial is a poor guide to what is in it.

What is genuinely unknown should be stated plainly. There is no pharmacokinetic study of KPV in humans, no dose-ranging or tolerability study in any species, no chronic-exposure data, and no published intranasal study despite nasal products being sold. Every animal study located was designed to measure an efficacy endpoint, so nothing here amounts to a search for harm that came back empty. Research use only, and not medical advice.

KPV is a naturally occurring tripeptide corresponding to the C-terminal three residues (lysine-proline-valine) of alpha-melanocyte-stimulating hormone (alpha-MSH). The anti-inflammatory activity of this minimal fragment grew out of research in the 1980s and 1990s into the immunomodulatory properties of alpha-MSH, associated with investigators such as Thomas Luger, Thomas Brzoska, and James Lipton. A key demonstration came in 2008, when Kannengiesser, Maaser, and colleagues showed that KPV reduced inflammation in murine models of inflammatory bowel disease, partly independent of the melanocortin-1 receptor. More recently it has become a favored payload for targeted nanoparticle and hydrogel delivery systems aimed at ulcerative colitis.

KPV is valued as a compact, potent anti-inflammatory peptide that retains much of the immunomodulatory power of its parent hormone in just three amino acids. It is especially appreciated for a targeted mode of action; rather than broadly suppressing immunity, it dampens the specific NF-kB and cytokine signaling that drives inflammatory tissue damage, and it concentrates its effect where inflammation is active in the gut via the PepT1 transporter. Its small size, oral stability, and clean mechanism have made it a popular candidate in research on inflammatory bowel and skin conditions. As with most peptides in this space, robust human clinical data are still limited.